SK Bioscience's shingles vaccine obtains product approval from Malaysia

It is the second time that Sky Zoster has been approved overseas after Thailand in May 2020

SK Bioscience's Sky Zoster
SK Bioscience's Sky Zoster
Jung-Eun Kim 1
2023-01-09 16:22:37 likesmile@hankyung.com
Bio & Pharma

SK Bioscience Co. said on Monday that its shingles vaccine Sky Zoster has been given approval by Malaysia's National Pharmaceutical Regulatory Agency.

Sky Zoster is a live attenuated vaccine developed by SK Bioscience with its proprietary technology and was approved by the Korean Ministry of Food and Drug Safety in 2017.

It is the second time that Sky Zoster has been approved overseas after Thailand in May 2020.

SK Bioscience will apply for pre-qualification (PQ) for Sky Zoster with the World Health Organization this year.

PQ is a system by which the WHO evaluates the safety and effectiveness before supplying vaccines and medicines to developing countries.

“We will expand the products based on our technology as much as possible given our company's status in the world market has been upgraded after consignment production and self-development of COVID vaccines," said Ahn Jae-yong, CEO of SK Bioscience. 

Write to Jung-Eun Kim at likesmile@hankyung.com
#SK Bioscience #National Pharmaceutical Regulatory Agency #Sky Zoster #shingles vaccine #korea sk bioscience skyzoster vaccine #korea sk bioscience shingles vaccine

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience seeks WHO nod for prompt COVID vaccine sale

SK Bioscience’s production line of SKYCovione in South Korea (Courtesy of Yonhap) SK Bioscience Co., the biopharmaceutical unit of South Korea’s No. 2 conglomerate SK Group, sought approval from the World Health Organization (WHO) for the immediate sale of the company’s COVID-

SK Bioscience wins marketing license for Korea's first COVID-19 vaccine

SK Bioscience wins marketing license for Korea's first COVID-19 vaccine

SKYCovione, SK Bioscience's COVID-19 vaccine (Courtesy of SK Bioscience) South Korea’s SK Bioscience Co., a biopharmaceutical unit of SK Group, has won marketing authorization for its COVID-19 vaccine from the Ministry of Food and Drug Safety (MFDS) of Korea on Wednesday. MFDS approved th

SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector

SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector

SK Bioscience CEO Ahn Jae-yong unveils the company's long-term business plans SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand its business portfolio from contract manufacturing to gene therapy deve

SK Bioscience becomes first to win domestic COVID-19 vaccine contract 

SK Bioscience becomes first to win domestic COVID-19 vaccine contract 

SK Bioscience facility in North Gyeongsang Province SK Bioscience Co. said it reached a deal with Korea’s disease control agency to supply 10 million doses of the country’s first experimental COVID-19 vaccine.This is the first time a vaccine developed by a South Korean company has s
(* comment hide *}